Is BPC-157 safe for dogs?
The short answer
BPC-157 has the most directly relevant safety data of any compound on this site as it applies to dogs. A dedicated preclinical toxicity evaluation covering mice, rats, rabbits and dogs reported that it was well tolerated with no serious toxicity, no genotoxicity and no embryo-fetal toxicity; the single notable finding was a decrease in creatinine at 2 mg/kg, which resolved spontaneously after two weeks of withdrawal and did not occur at lower doses. Local irritation was mild. The meaningful caveat is duration rather than dose — those studies covered single and repeated dosing, not months of continuous administration.
Additional cautions
Limited long-term canine data
The published canine work covers short-duration dosing. Multi-month continuous administration in dogs has not been formally studied, so extended use should be a deliberate decision made with your veterinarian rather than a default.
Angiogenic mechanism has not been evaluated in cancer
No cancer contraindication is established for BPC-157, and its preclinical safety work reported no tumour-promoting signal. It is still worth being explicit about why the question comes up: the angiogenesis this compound is investigated for is the same process that makes TB-500 contraindicated in malignancy. The difference is that BPC-157 has not been formally evaluated in that setting, not that it has been cleared. In a dog with known or suspected cancer this is a question for a veterinary oncologist rather than an assumption in either direction.
What the evidence base actually is
Safety claims are only as good as the studies behind them.
BPC-157 is a short chain of fifteen amino acids originally identified in gastric juice. Research describes it encouraging the growth of new blood vessels into damaged tissue, which is the rate-limiting step in most healing. Studies also report a protective effect on the lining of the gut. It is the one compound here with a published pharmacokinetic study performed in dogs, which is why it appears first on almost every canine protocol.
Dosing context
Safety is dose-dependent. These are the figures reported in the source literature.
Small / toy breed
under 22 lb (10 kg)
- Reported dose
- 4–100 mcg per day
- Frequency
- Once daily
- Duration
- 2-4 weeks
- Studied for
- Gastrointestinal issues, joint injury, post-surgical recovery
Medium breed
22–77 lb (10–35 kg)
- Reported dose
- 20–350 mcg per day
- Frequency
- Once daily
- Duration
- 2-8 weeks
- Studied for
- Tendon and ligament injury, gut protection, wound healing
Large / giant breed
over 77 lb (35 kg)
- Reported dose
- 70–600 mcg per day
- Frequency
- Once daily
- Duration
- 2-8 weeks
- Studied for
- Orthopaedic recovery, chronic degenerative conditions
See the full BPC-157 profile for mechanism, protocol and monitoring detail.
Common questions
Is BPC-157 safe for dogs?+
BPC-157 has the most directly relevant safety data of any compound on this site as it applies to dogs. A dedicated preclinical toxicity evaluation covering mice, rats, rabbits and dogs reported that it was well tolerated with no serious toxicity, no genotoxicity and no embryo-fetal toxicity; the single notable finding was a decrease in creatinine at 2 mg/kg, which resolved spontaneously after two weeks of withdrawal and did not occur at lower doses. Local irritation was mild. The meaningful caveat is duration rather than dose — those studies covered single and repeated dosing, not months of continuous administration.
What are the side effects of BPC-157 in dogs?+
Limited long-term canine data: The published canine work covers short-duration dosing. Multi-month continuous administration in dogs has not been formally studied, so extended use should be a deliberate decision made with your veterinarian rather than a default. Angiogenic mechanism has not been evaluated in cancer: No cancer contraindication is established for BPC-157, and its preclinical safety work reported no tumour-promoting signal. It is still worth being explicit about why the question comes up: the angiogenesis this compound is investigated for is the same process that makes TB-500 contraindicated in malignancy. The difference is that BPC-157 has not been formally evaluated in that setting, not that it has been cleared. In a dog with known or suspected cancer this is a question for a veterinary oncologist rather than an assumption in either direction.
Can BPC-157 be given to a dog with cancer?+
No cancer-specific contraindication is established for BPC-157 in the published literature. Any dog with a diagnosed malignancy should nevertheless have its full protocol reviewed by the veterinarian managing the case, since interactions with active treatment are not well characterised.
Does my dog need testing before starting BPC-157?+
No compound-specific genetic testing is established for BPC-157. Baseline bloodwork before starting, and repeat testing during a protocol, is standard practice and lets your veterinarian catch a problem before it becomes clinically apparent.
References
- 1.CANINE STUDYHe L, Feng D, Guo H, et al. Pharmacokinetics, distribution, metabolism, and excretion of body-protective compound 157, a potential drug for treating various wounds, in rats and dogs. Frontiers in Pharmacology, 2022. PMID 36588717
- 2.CANINE STUDYXu C, Sun L, Ren F, et al. Preclinical safety evaluation of body protective compound-157, a potential drug for treating various wounds. Regulatory Toxicology and Pharmacology, 2020. PMID 32334036
- 3.Vasireddi N, Nguyen HH, Ahmed WA, et al. Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review. HSS Journal, 2025. PMID 40756949
- 4.Gwyer D, Wragg NM, Wilson SL Gastric pentadecapeptide body protection compound BPC 157 and its role in accelerating musculoskeletal soft tissue healing. Cell and Tissue Research, 2019. PMID 30915550
- 5.Józwiak M, Bauer M, Kamysz W, Kleczkowska P Multifunctionality and Possible Medical Application of the BPC 157 Peptide — Literature and Patent Review. Pharmaceuticals, 2025. PMID 40005999
- 6.Mayfield CK, et al. Injectable Peptide Therapy: A Primer for Orthopaedic and Sports Medicine Physicians. American Journal of Sports Medicine, 2026. PMID 41476424
Educational information — not veterinary medical advice
Everything on this page is compiled from published peer-reviewed literature for educational and research purposes. It does not establish a veterinarian-client-patient relationship (VCPR) and is not a substitute for veterinary examination and diagnosis. Most compounds described here are investigational or used off-label and are not FDA-approved for these purposes in dogs. Extralabel drug use in animals requires a valid VCPR and the direct supervision of a licensed veterinarian under AMDUCA (21 U.S.C. §360b). Dosing figures are reported as they appear in the source literature and are not recommendations.